



Vol.2, Issue 2 | April-June 2026

# Pan-African Journal of Health And Psychological Sciences

ISSN: 3093-4737 | www.pajhps.org



## Unifying Herbal Medicine and Modern Pharmaceutical Delivery Via Curcumin Transdermal Patches

Author(s): Ravneet Kaur<sup>1</sup>, Sehrabpreet Singh<sup>2</sup>, Shruti<sup>3</sup>, Amanpreet Singh<sup>4</sup>

<sup>1</sup>Student, BSC Pharmacy, Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar (140111) Punjab, India,

<sup>2</sup>Assistant Professor, Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar (140111) Punjab, India

<sup>3</sup>Assistant Professor, Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, Punjab, India, PIN: 140111

<sup>4</sup>Research Scholar, Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, Punjab, India, PIN: 140111

### Corresponding Author\*

**Sehrabpreet Singh**

Email: [sehrabpreetsingh@gmail.com](mailto:sehrabpreetsingh@gmail.com)

### Abstract

Traditional herbal therapy has long praised curcumin, the main bioactive component of *Curcuma longa*, for its anti-inflammatory, antioxidant, and wound-healing qualities. However, due to its weak water solubility, rapid metabolism, and limited systemic availability when administered orally, its therapeutic potential has remained limited. Transdermal drug delivery systems (TDDS), which provide patient-friendly dosing, enhanced bioavailability, and controlled penetration, have emerged as a revolutionary approach to overcoming these limitations. Transdermal curcumin patches are an inventive fusion of traditional phytotherapy and contemporary pharmaceutical technologies. To efficiently transport curcumin across the stratum corneum, these patches are designed with polymeric matrices, permeation enhancers, and adhesive coatings. The patches enhance therapeutic efficacy while minimizing gastrointestinal distress by bypassing hepatic first-pass metabolism and maintaining consistent plasma concentrations. Curcumin-loaded nanoparticles, nano-emulsions, and microneedle-assisted systems are recent developments in nanotechnology that further enhance skin penetration

How to cite this article: Kaur et al. (2026). **Unifying Herbal Medicine and Modern Pharmaceutical Delivery Via Curcumin Transdermal Patches**. *Pan-African Journal of Health and Psychological Sciences*. Vol.2, Issue 2, April-June 2026.  
<https://doi.org/10.64261/40brt540>.

and stability, broadening their potential clinical uses in dermatological disorders, chronic inflammation, pain management, and systemic conditions that need long-term therapy. Furthermore, the use of herbal-compatible and biodegradable polymers is in line with the increasing need for sustainable and biocompatible medication delivery systems across the world. Early clinical evaluations show better patient compliance and treatment outcomes, while preclinical studies show encouraging findings in terms of safety, permeation efficiency, and pharmacodynamic activity. Despite these benefits, there are still issues with long-term clinical validation, regulatory procedures, stability optimization, and large-scale production. All things considered, curcumin transdermal patches represent a significant advancement in fusing conventional herbal knowledge with cutting-edge medication delivery technology. They are positioned as a potential frontier in herbal-based pharmaceutical innovation because of their capacity to transform a centuries-old natural medicine into a precisely regulated medicinal system.

**KEYWORDS:** Controlled Release, Curcumin, Nanotechnology, Phytomedicine, Polymeric Patch, Skin Penetration, Transdermal Drug Delivery.

## 1. Introduction

The integration of traditional herbal medicine with modern pharmaceutical sciences represents a promising paradigm for the development of safer, effective, and patient-friendly therapeutic systems. Herbal medicines have been used for centuries across various cultures, particularly in Ayurveda, Traditional Chinese Medicine, and Unani systems, where plant-derived compounds have demonstrated significant therapeutic potential in the management of chronic and acute diseases [1]. Due to their wide range of pharmacological actions, comparatively low toxicity, and superior patient acceptability over synthetic pharmaceuticals, herbal medicines have attracted increased scientific attention in recent decades [2]. Nevertheless, despite their benefits, many herbal substances have drawbacks that limit their clinical use, including poor solubility, limited bioavailability, fast metabolism, and uneven therapeutic results [3]. Because of its many pharmacological characteristics, curcumin, a naturally occurring polyphenolic chemical extracted from the rhizomes of *Curcuma longa* (turmeric), is one of the most researched herbal compounds. Strong anti-inflammatory, antioxidant, anticancer, antibacterial, wound-healing, and neuroprotective properties are demonstrated by curcumin [4,5]. Abundant conditions, such as arthritis, cardiovascular illnesses, metabolic syndrome, neurological diseases, and different types of cancer, have demonstrated its therapeutic potential [6].

Curcumin's poor water solubility, limited oral bioavailability, quick systemic elimination, and substantial first-pass metabolism have significantly hindered its clinical translation despite these encouraging biological properties [7]. These difficulties call for the creation of cutting-edge drug delivery methods that can improve curcumin's therapeutic effectiveness.

By enhancing medication stability, bioavailability, controlled release, and targeted administration, contemporary pharmaceutical delivery methods seek to get beyond these restrictions. The capacity of transdermal drug delivery systems (TDDS) to transfer pharmaceuticals via the skin into systemic circulation while bypassing gastrointestinal degradation and hepatic first-pass metabolism has drawn a lot of attention among numerous new drug delivery methods [8]. Sustained medication release, more patient compliance, fewer doses, and less systemic adverse effects are only a few benefits of transdermal patches [9]. These characteristics make TDDS especially appropriate for long-term treatment for chronic illnesses. Conversely, the stratum corneum, which restricts the transdermal transport of many medicinal drugs, particularly hydrophobic compounds like curcumin, makes the human skin a major obstacle to drug penetration [10]. Transdermal systems for herbal medicines are now much more feasible thanks to developments in formulation science, such as the use of penetration enhancers, polymeric matrix, nanocarriers, and microneedle-assisted delivery [11]. Curcumin can be included into transdermal patches to improve skin penetration, sustain therapeutic plasma concentrations, and produce long-lasting pharmacological activity. Transdermal patches filled with curcumin are an innovative way to combine current pharmaceutical technology with traditional herbal treatment. These technologies provide a matrix that regulates drug release and improves stability by using biocompatible polymers such ethyl cellulose, hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol, and chitosan [12].

Furthermore, it has been demonstrated that curcumin skin penetration may be greatly increased without causing severe irritation by utilizing chemical permeation enhancers including terpenes, fatty acids, and surfactants [13]. These formulation techniques guarantee constant dosage and better therapeutic results in addition to increasing curcumin's bioavailability.

From a therapeutic standpoint, transdermal curcumin administration has potential for treating inflammatory conditions, localized pain, wound healing, psoriasis, and even symptoms associated with cancer, when a prolonged and targeted pharmacological effect is desired [14]. Additionally, transdermal methods enhance patient adherence, especially in older and chronically sick patients, and lessen gastrointestinal adverse


effects that are frequently linked to oral curcumin supplementation [15]. Transdermal patches' non-invasiveness increases their acceptance and long-term applicability. The integration of sophisticated medication delivery technologies with herbal medicine is in line with the increasing need for evidence-based and integrative healthcare solutions worldwide. To guarantee safety and effectiveness, researchers and regulatory bodies are placing more emphasis on the scientific validation, standardization, and quality control of herbal formulations [16]. By providing repeatable, stable, and clinically viable solutions, the integration of herbal active ingredients like curcumin into well-studied pharmaceutical delivery systems like transdermal patches allays these worries.

## **2. Historical Background of Curcumin & Transdermal Therapy**

The main bioactive component of *Curcuma longa*, or turmeric, is curcumin, which has been used medicinally for over 4,000 years in ancient systems, including Ayurveda, Siddha, and traditional Chinese Medicine. Turmeric's wide range of medicinal applications is evident in its historical use for wound healing, inflammation, skin diseases, respiratory illnesses, and digestive issues [17]. Curcumin was initially isolated in 1815 by Vogel and Pelletier, and its chemical structure was discovered in 1910 [18]. This marked the beginning of curcumin's scientific investigation in the early 19th century. Its anti-inflammatory, antioxidant, antibacterial, and anticancer qualities were validated by further pharmacological studies conducted during the 20th century, which led to its acknowledgement as a useful phytochemical in contemporary medicine [19]. Curcumin's poor water solubility, volatility, fast metabolism, and low systemic bioavailability after oral dosing have hampered its clinical utilization despite its wide therapeutic potential [20]. Conversely, transdermal treatment is an old medicinal method that is quite recent. Ancient Egyptian, Greek, and Chinese medical books described early topical treatments, including herbal poultices, ointments, and medicinal plasters, in which medications were applied directly to the skin for both regional and systemic effects [21]. The US FDA approved the first transdermal patch (scopolamine) in 1979, marking the culmination of the scientific development of transdermal medication delivery methods in the second half of the 20th century [22]. Since then, transdermal treatment has evolved into a dependable and advanced drug delivery system because to developments in polymer science, skin permeability enhancers, and controlled-release technologies [23]. The strategic development of curcumin's historic herbal heritage and contemporary transdermal technology aims to overcome bioavailability issues without compromising its medicinal efficacy.



**Figure No.1: Curcumin in Powder Form**



**FIGURE NO.2: STRUCTURE OF CURCUMIN AND ITS DERIVATIVES**

### 3. Evolution of Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) have evolved as a result of important developments in pharmaceutical sciences that are intended to increase patient compliance and therapeutic efficacy. Traditional topical treatments including ointments, plasters, and herbal poultices used for localized therapy in ancient societies served as the model for early transdermal therapies [24]. Recent TDDS was made possible by scientific discoveries about the structure and permeability of skin in the middle of

How to cite this article: Kaur et al. (2026). **Unifying Herbal Medicine and Modern Pharmaceutical Delivery Via Curcumin Transdermal Patches**. *Pan-African Journal of Health and Psychological Sciences*. Vol.2, Issue 2, April-June 2026. <https://doi.org/10.64261/40brt540>.

the 20th century, which resulted in the creation of controlled drug release systems [25]. An important turning point in systemic medication administration through the skin was reached in 1979 with the approval of the first transdermal patch containing scopolamine [26].

The development of matrix, reservoir, and drug-in-adhesive patch systems with enhanced stability and release kinetics was made possible by later advances in polymer technology [27]. The skin penetration of medications with low permeability was further improved by the addition of chemical permeation enhancers such as alcohols, fatty acids, and terpenes [28]. The variety of medications appropriate for transdermal administration has increased due to developments in physical enhancement methods such as iontophoresis, sonophoresis, electroporation, and microneedles [29]. To increase bioavailability and targeted administration, TDDS has more recently included nanocarrier-based systems such as liposomes, ethosomes, and nanoemulsions [30]. Transdermal medication delivery is now a flexible and therapeutically successful platform for both synthetic and natural therapies because to these advancements.

#### **4. Integration of Herbal Medicine with Advanced Tdds**

A promising approach to overcoming the drawbacks of traditional herbal dosage forms, such as low bioavailability, extensive first-pass metabolism, and inconsistent therapeutic plasma levels, is the integration of herbal medicine with cutting-edge transdermal drug delivery systems (TDDS). By delivering herbal bioactives directly via the skin into the systemic circulation in a regulated and sustained manner, TDDS provides a non-invasive method that can improve patient compliance, decrease systemic adverse effects, and increase therapeutic efficacy [31]. According to recent reviews, adding herbal extracts to matrix-type patches, nanoemulsions, liposomes, and other sophisticated TDDS platforms not only increases skin penetration by using both natural and synthetic polymers, but also uses herbal permeation enhancers to increase transdermal absorption [32,33]. By preventing phytoconstituents from degrading and facilitating targeted release, innovations like nanocarrier-based systems, such as solid lipid nanoparticles and nanostructured lipid carriers, further enhance the transport of complex herbal actives [34].

The combination of traditional herbal medicine with cutting-edge TDDS technology is becoming more widely acknowledged as a practical strategy to modernize

phytotherapeutics and increase their clinical applicability, despite persistent difficulties with standardization and regulatory acceptability [32,33].

## 5. Anatomy and Physiology of The Skin Relevant to Transdermal Delivery


As the body's main line of defense, the skin is a sophisticated, multipurpose organ that is essential to transdermal drug delivery systems (TDDS). The epidermis, dermis, and hypodermis are the three primary layers that make up the skin anatomically. The primary barrier to drug penetration is the epidermis, namely the stratum corneum, which is its outermost layer. The "brick and mortar" model of the stratum corneum, which is made up of dead, flattened keratinocytes (corneocytes) embedded in a lipid-rich matrix primarily composed of ceramides, cholesterol, and free fatty acids, greatly limits the penetration of hydrophilic and large molecular weight medications [35,36].

The viable epidermis and dermis, which are more porous and include blood arteries, lymphatics, nerve endings, and connective tissue that aid in systemic absorption once the medication passes through the stratum corneum, are located underneath the epidermis [37]. The hypodermis, which is mostly made up of adipose tissue, serves as a pharmacological reservoir for lipophilic substances and offers mechanical support. Transdermal medication absorption is physiologically influenced by variables including skin moisture, thickness, lipid content, pH, temperature, and local blood flow [38]. Furthermore, alternate shunt channels for drug penetration are provided by skin appendages such as sweat glands and hair follicles, particularly for macromolecules and nanoparticles [39].

### 5.1. Skin Structure

The epidermis, dermis, and hypodermis are the three separate layers that make up the skin, which is the biggest organ in the body. Each layer contributes to the skin's barrier and physiological functions. The stratum corneum serves as the main barrier to substances from the outside world. The outermost layer of the epidermis is a stratified squamous epithelium made mostly of keratinocytes. This layer, which prevents medicines and xenobiotics from penetrating, is made up of terminally differentiated corneocytes embedded in a lipid matrix rich in ceramides, cholesterol, and fatty acids [40,41]. Collagen and elastin fibers, blood arteries, lymphatics, and nerve endings make up the dermis, a layer of connective tissue that lies underneath the epidermis. Once the epidermal barrier is overcome, the dermis facilitates systemic medication absorption and provides structural support [42]. Adipose tissue makes up the majority of the

hypodermis, which acts as a mechanical cushion, insulating layer, and possible drug reservoir, especially for lipophilic substances [43]. Moreover, these layers are penetrated by skin appendages like sweat glands and hair follicles, which provide different routes for penetration, particularly for particulate and macromolecular delivery systems [44].




**Figure 3: Human Skin Anatomy**

### 5.2. Barrier Role of The Stratum Corneum

The stratum corneum is the skin's main barrier and the main layer that limits the pace at which drugs are delivered transdermally. Its distinctive "brick and mortar" structure is made up of terminally differentiated, keratin-filled corneocytes embedded in a highly organized lipid matrix mostly comprised of ceramides, cholesterol, and free fatty acids [45,46]. This special structure limits the penetration of exogenous chemicals, especially hydrophilic and high-molecular-weight medications, while also decreasing transepidermal water loss [47]. Although transcellular and appendageal pathways may potentially aid in penetration, the intercellular lipid pathway is primarily responsible for drug transport across the stratum corneum [48]. Changes in the stratum corneum's thickness, integrity, hydration level, and lipid content have a substantial impact on its barrier qualities and, in turn, transdermal medication absorption [49].

### Figure.4: Factors Influencing Skin Permeation

Skin permeation depends on several physicochemical parameters:



Curcumin's lipophilicity ( $\log P = 3.2$ ) makes it suitable for transdermal delivery when formulated with appropriate carriers.

### 5.3. Rationale for Transdermal Delivery of Curcumin

*Curcuma longa* is the source of curcumin, a polyphenolic compound with a wide range of pharmacological activities, such as anti-inflammatory, antioxidant, anticancer, and wound-healing effects. Nevertheless, its poor aqueous solubility, low chemical stability, extensive first-pass metabolism, and very low oral bioavailability severely restrict its clinical application [50,51]. By avoiding hepatic metabolism and gastrointestinal breakdown, transdermal medication administration provides a viable substitute that enhances systemic availability and sustains plasma drug levels [52]. Furthermore, transdermal distribution improves patient compliance by reducing dose-related adverse effects and enabling regulated, non-invasive administration [53]. When paired with formulation techniques like penetration enhancers, nanoparticles, or polymeric patches to get beyond the stratum corneum barrier, curcumin's advantageous molecular weight and lipophilicity make it a good option for transdermal systems [54].

### 6. Limitations of Oral Curcumin Administration

Curcumin has very low bioavailability due to its poor water solubility, minimal intestinal absorption, fast metabolism, and systemic elimination. In the colon and liver, curcumin is rapidly converted to glucuronide and sulfate metabolites with decreased pharmacological action after extensive first-pass metabolism [55,56].


Curcumin's effective concentration in the systemic circulation is further decreased by the fact that it is chemically unstable at physiological pH and prone to breakdown in the gastrointestinal environment [57]. Due to these restrictions, substantial oral dosages are

required to provide therapeutic benefits, which may cause gastrointestinal distress and low patient compliance [58].

Therefore, to improve curcumin's therapeutic effectiveness, other administration methods are needed [59].

#### **FIGURE NO.5: ADVANTAGES OF TRANSDERMAL DELIVERY**

Transdermal delivery addresses these limitations by:



#### **FIGURE NO.6: CONDITIONS BENEFITING FROM TRANSDERMAL CURCUMIN**

Curcumin patches are promising for:




These applications leverage curcumin's multifaceted pharmacological properties and TDDS targeted delivery approach.

## 7. TYPES OF TRANSDERMAL SYSTEMS USED FOR CURCUMIN

- 7.1. Polymeric Transdermal Patches:** In order to provide curcumin with longer-lasting drug release, better stability, and more patient compliance, matrix- and reservoir-type polymeric patches have been investigated. Curcumin penetration is improved and the stratum corneum barrier is broken down with the use of plasticizers and penetration enhancers [60].
- 7.2. Nanoparticle-Based Systems:** By increasing surface contact and enhancing drug solubility and stability, curcumin-loaded nanoparticles, such as polymeric nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers, improve skin penetration [61,62].
- 7.3. Nanoemulsions and Microemulsions:** Because of their tiny droplet size and great thermodynamic stability, these systems enhance curcumin's solubilization and promote its diffusion over the skin, making them appropriate for topical and transdermal applications [63].
- 7.4. Liposomes and Phytosomes:** By imitating biological membranes and enhancing drug–lipid interactions within the stratum corneum, vesicular carriers like liposomes and phytosomes improve curcumin's skin penetration [64].

- 7.5. Microneedle-Based Systems:** By creating microchannels in the skin, microneedle arrays circumvent the stratum corneum barrier and greatly improve the transdermal distribution of substances that are weakly permeable, such as curcumin [65].
- 7.6. Ethosomes:** Compared to traditional liposomes, ethosomes are soft, ethanol-rich vesicular carriers that increase curcumin permeability by fluidizing the stratum corneum lipids, resulting in deeper skin penetration and better bioavailability [66].
- 7.7. Transfersomes:** These highly deformable vesicles can effectively transfer curcumin across intact skin with improved penetration efficiency because they can squeeze through the stratum corneum's tiny intercellular crevices [67].
- 7.8. Proniosomes and Niosomes:** These non-ionic surfactant-based vesicles increase transdermal flow, regulate drug release, and stabilize curcumin while lowering formulation-related toxicity [68].
- 7.9. Hydrogels and Nanogels:** Curcumin-loaded hydrogels and nanogels increase drug residence duration at the application site, improve skin hydration, and distribute drugs locally and sustainably [69].
- 7.10. Iontophoresis-Assisted Systems:** Iontophoresis uses a low electrical current to improve curcumin's transdermal transport, which is especially helpful for increasing flux and accomplishing regulated, on-demand medication administration [70].
- 7.11. Sonophoresis (Ultrasound-Assisted administration):** Sonophoresis increases skin permeability and improves the transdermal administration of curcumin by using ultrasound waves to momentarily disturb the stratum corneum structure [71].



**Figure 7: Types Of Tdds**

## 8. Physicochemical Properties of Curcumin Relevant to Tdds

The yellow-orange crystalline polyphenol curcumin (diferuloylmethane;  $C_{21}H_{22}O_4$ ) has a molecular weight of 368.38 g/mol, which is within the permissible range for transdermal drug delivery methods [72]. Although its very low water solubility ( $\approx 0.6\text{--}1\ \mu\text{g/mL}$ ) restricts diffusion into deeper hydrophilic skin layers, its high lipophilicity ( $\log P\ 3.0\text{--}4.5$ ) encourages partitioning into the lipid-rich stratum corneum [73,74]. Curcumin's permeability behavior is further influenced by its pKa values, which range from 8.5 to 9.9 and remain mostly unionized at physiological skin pH [75]. Protective formulation techniques are required in TDDS since the molecule is chemically unstable, sensitive to light, heat, and alkaline environments, and degrades into compounds such as ferulic acid and vanillin [76]. Curcumin's limited permeability across biological membranes underscores the need for penetration enhancers, vesicular carriers, or nanostructured devices to ensure efficient transdermal distribution, despite its advantageous molecular size and lipophilicity [77].

**TABLE 1: PHYSICOCHEMICAL PROPERTIES OF CURCUMIN**

S.No	PROPERTIES	DETAILS/VALUES
1.	<b>Chemical Name</b>	Diferuloylmethane
2.	<b>Chemical Formula</b>	$C_{21}H_{20}O_6$
3.		

How to cite this article: Kaur et al. (2026). **Unifying Herbal Medicine and Modern Pharmaceutical Delivery Via Curcumin Transdermal Patches**. *Pan-African Journal of Health and Psychological Sciences*. Vol.2, Issue 2, April-June 2026. <https://doi.org/10.64261/40brt540>.

	<b>Molecular Weight</b>	368.38 /mol
4.	<b>Appearance</b>	Yellow-orange crystalline powder
5.	<b>Melting Point</b>	183-185°C
6.	<b>Solubility</b>	Very low in water ( $\approx 0.6-1 \mu\text{g/mL}$ ); soluble in ethanol
7.	<b>Log P (Partition coefficient)</b>	3.0-4.5 (highly lipophilic)
8.	<b>pKa Values</b>	pKa <sub>1</sub> $\approx$ 8.5, pKa <sub>2</sub> $\approx$ 9.9
9.	<b>Stability</b>	Sensitive to light, heat, and alkaline pH; degrades to vanillin, ferulic acid, and ferloylmethane.
10.	<b>Color Index</b>	Natural yellow pigment from turmeric ( <i>Curcuma longa</i> ).
11.	<b>Permeability Nature</b>	Naturally low across biological membranes without enhancers.

## 9. Formulation Components of Curcumin Transdermal Patches


Curcumin TDDS are made up of a number of crucial elements that work together to provide improved permeation, stability, controlled release, and efficient adhesion.

**9.1. Active Pharmaceutical Ingredient (Curcumin):** Because of its strong anti-inflammatory, antioxidant, antibacterial, and anticancer properties, curcumin is the medicinal ingredient used in transdermal patches. However, careful drug loading optimization is required due to its low stability, restricted skin permeability, and poor water solubility. To improve solubility, stability, and transdermal flow, curcumin can be added in free form or as complexes, nanoparticles, or solid dispersions [78,79].

**9.2. Polymeric Matrix / Film-Forming Polymers:** The foundation of transdermal patches is the polymeric matrix, which controls patch integrity, drug release kinetics, and mechanical strength. Hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), ethyl cellulose, polyvinyl alcohol (PVA), and Eudragit®

polymers are examples of hydrophilic and hydrophobic polymers that are often used. Curcumin's controlled release characteristics, moisture absorption, and film flexibility are frequently balanced by blending polymers [80,81].

- 9.3. Plasticizers:** In order to prevent brittleness during storage and usage, plasticizers are added to the polymeric film to increase its elasticity and flexibility. Glycerol, propylene glycol, polyethylene glycol (PEG-400), and dibutyl phthalate are common plasticizers. Plasticizers can improve curcumin release and facilitate drug diffusion by increasing polymer chain mobility in addition to improving mechanical characteristics [82].
- 9.4. Penetration Enhancers:** In order to get beyond the stratum corneum's barrier function, penetration enhancers are essential. Chemical enhancers including oleic acid, ethanol, dimethyl sulfoxide (DMSO), terpenes, and Transcutol® P boost drug partitioning, disturb the stratum corneum's lipid architecture, and improve curcumin's transdermal flux. The selection and concentration of enhancers must be optimized to achieve effective permeation without causing skin irritation [83,84].
- 9.5. Adhesive Layer:** Pressure-sensitive adhesives ensure intimate contact between the patch and the skin, which is essential for consistent drug delivery. Acrylic, silicone, and polyisobutylene-based adhesives are commonly used due to their good adhesion, flexibility, and skin compatibility. In some designs, the adhesive layer may also contain curcumin, forming a drug-in-adhesive system [85].
- 9.6. Backing Membrane:** The backing membrane shields the formulation from external elements like moisture and oxygen while also giving the patch structural stability. Additionally, it stops medication loss from the patch's outside. Because of their mechanical durability and impermeability, materials including polyester, polyethylene, and aluminized films are frequently utilized [86].
- 9.7. Release Liner:** During storage, the release liner acts as a protective covering for the patch's adhesive surface. It is removed just before application. Silicone-coated paper or polymer films are typically used to ensure easy removal without affecting adhesive properties [87].




**Figure 8: Structure and Components Of Transdermal Patch**

### **10. Advanced Nanotechnology-Based Curcumin Patch Enhancements**

By decreasing particle size, boosting skin penetration, and enhancing solubility, nanotechnology greatly improves curcumin administration.

- 10.1. Polymeric Nanoparticle-Loaded Patches:** Transdermal patches containing curcumin-loaded polymeric nanoparticles (such as PLGA and chitosan) increase drug solubility, shield curcumin from deterioration, and offer continuous and regulated release, which improves skin penetration [88].
- 10.2. Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs):** By promoting robust interactions with stratum corneum lipids, SLNs and NLCs enhance curcumin stability and skin retention, leading to increased penetration and extended therapeutic effect [89].
- 10.3. Liposome-Integrated Patches:** Liposomes are a good option for long-term transdermal administration because they resemble biological membranes and improve curcumin penetration via better drug partitioning into skin lipids while lowering irritation [90].

- 10.4. Ethosome-Based Patch Systems:** When added to patch matrices, ethosomes, which have a high ethanol concentration, fluidize stratum corneum lipids and greatly increase curcumin's deep skin penetration [91].
- 10.5. Transfersome-Enhanced Patches:** Curcumin may be effectively delivered across intact skin with enhanced transdermal flux thanks to transfersomes, which are highly deformable vesicles that can pass through small intercellular gaps [92].
- 10.6. Nanoemulsion and Nanogel-Based Patches:** Together, nanoemulsions and nanogels improve transdermal penetration and bioavailability by increasing curcumin solubilization, skin hydration, and drug residence time [93].
- 10.7. Microneedle-Assisted Nanocarrier Patches:** By creating microchannels in the skin, curcumin nanocarriers and microneedle arrays circumvent the stratum corneum barrier and allow for more effective drug administration with less invasiveness [94].



**Figure 9: Nanocurcumin Advanced Technologies**

## 11. Mechanism of Drug Release and Skin Permeation

Drug release and skin penetration in transdermal drug delivery systems are accomplished via a sequence of diffusion-controlled procedures that are regulated by Fick's diffusion laws. The medication leaves the patch matrix or reservoir after application, diffuses through the stratum corneum, the skin's main barrier layer, passes through the viable epidermis and dermis, and then enters the bloodstream through

dermal capillaries [95,96]. Drug physicochemical characteristics, such as molecular weight, lipophilicity, and ionization state, determine skin penetration, whereas formulation parameters, such as polymer type, drug–polymer interactions, and the presence of penetration enhancers, affect the rate of drug release [97]. Drug partitioning and diffusion across the skin barrier can be increased by penetration enhancers, vesicular carriers, and nanocarriers that alter the lipid architecture of the stratum corneum [98]. In general, effective penetration through epidermal layers and regulated drug release from the patch are important factors that determine therapeutic effectiveness in transdermal administration systems [99].

**Table 2: Evaluation Parameters for Curcumin Transdermal Patches with Standard Values**

<b>Sr. No.</b>	<b>Evaluation Parameter</b>	<b>Detailed Description</b>	<b>Standard / Expected Value Range</b>
<b>1.</b>	<b>Physical Appearance</b>	Checks color, uniformity, smooth texture, absence of air bubbles or cracks.	Uniform yellow–orange, smooth surface, no crystals, no cracks
<b>2.</b>	<b>Thickness</b>	Measures thickness at multiple points to ensure uniformity and dose accuracy.	0.2–0.5 mm (Deviation $\leq \pm 5\%$ )
<b>3.</b>	<b>Weight Variation</b>	Ensures a consistent mass of each patch for accurate dose.	Variation $\leq \pm 5\%$ of average weight
<b>4.</b>	<b>Moisture</b>	Indicates stability and protection from microbial growth.	2–5% moisture content
<b>5.</b>	<b>Folding Endurance</b>	Flexibility test: number of folds until break.	>250–300 folds without breaking
<b>6.</b>	<b>Drug Content Uniformity</b>	Ensures each patch contains an accurate	95–105% of labeled claim

		curcumin amount.	
7.	<b>Surface pH</b>	Prevents skin irritation; must be skin-compatible.	pH 5.5–6.5
8.	<b>Moisture Uptake</b>	Measures moisture absorption from the environment.	3–8% depending on polymer type
9.	<b>Tackiness Test</b>	Measures initial stickiness and ability to adhere to skin.	Should stick with light pressure; no residue (qualitative)
10.	<b>Tensile Strength</b>	Measures the mechanical strength of the patch.	2–5 kg/cm <sup>2</sup> depending on the polymer
11.	<b>In-Vitro Drug Release</b>	Determines the release kinetics of curcumin over time.	60–90% drug release in 8–24 hours
12.	<b>In-Vitro Skin Permeation</b>	Measures the amount of curcumin permeated through the skin.	Flux: <b>5–20 µg/cm<sup>2</sup>/hr</b> (enhancer-dependent)
13.	<b>Ex-Vivo Skin</b>	Checks for redness, itching, or swelling.	No erythema, no edema (Score <b>0</b> )
14.	<b>Water Vapour Transmission Rate (WVTR)</b>	Ensures breathability and skin comfort.	200–800 g/m <sup>2</sup> /day (polymer-dependent)
15.	<b>Stability Studies</b>	Checks stability under accelerated conditions (40°C ± 2°C/75% RH).	No major changes for <b>3–6 months</b>
16.	<b>Residual Solvent Analysis</b>	Ensures solvents are removed after	Within <b>ICH limits</b> (e.g., Ethanol <

		preparation.	<b>5000 ppm)</b>
<b>17.</b>	<b>Peel Adhesion Test</b>	Measures the force required to remove the patch without pain.	0.2–1.0 N/cm peel strength

## 12. Pharmacokinetic and Pharmacodynamic Considerations

When evaluating the therapeutic potential of curcumin administered by transdermal drug delivery systems (TDDS), pharmacokinetic and pharmacodynamic considerations are crucial. Avoiding gastrointestinal breakdown and substantial hepatic first-pass metabolism, which are the main causes of curcumin's low oral bioavailability, is one of the main pharmacokinetic benefits of transdermal delivery. Therefore, better systemic availability and more stable plasma drug concentrations over extended periods of time are made possible by transdermal administration [100,101]. Transdermal patches that release drugs continuously and under control guarantee steady-state drug levels, avoiding peak-trough swings and lowering the likelihood of dose-related toxicity or subtherapeutic exposure [102]. Formulation-dependent factors like polymer matrix properties, drug loading, permeation enhancers, and nanocarrier incorporation, as well as physiological factors like skin thickness, hydration level, regional blood flow, and inter-individual variability in skin barrier function, all affect the absorption kinetics of curcumin from TDDS [103,104].

From a pharmacodynamic perspective, transdermal administration of sustained plasma concentrations improves curcumin's therapeutic effectiveness by preserving a longer contact with its molecular targets. By modifying many signaling pathways, curcumin demonstrates pleiotropic pharmacological properties, including anti-inflammatory, antioxidant, antibacterial, anticancer, and neuroprotective effects. These include reduction of cyclooxygenase-2 (COX-2) and lipoxygenase enzymes, downregulation of pro-inflammatory cytokines including tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukins, inhibition of nuclear factor- $\kappa$ B (NF- $\kappa$ B), and control of apoptotic and cell proliferative pathways [105,106]. The possibility of systemic adverse effects linked to high oral dosage is decreased by the prolonged drug exposure that TDDS offers, which also improves pharmacodynamic responsiveness while permitting lower total drug doses [107]. Furthermore, higher patient adherence and the long-term therapeutic use of curcumin in chronic inflammatory, metabolic, and oncological illnesses are supported

by enhanced pharmacokinetic–pharmacodynamic alignment achieved by transdermal administration [108].

### **13. Clinical Applications and Therapeutic Benefits**

**Management of Inflammatory Disorders:** Psoriasis, osteoarthritis, and rheumatoid arthritis are among the chronic inflammatory diseases for which transdermal curcumin has demonstrated great promise. While reducing the gastrointestinal side effects linked to oral medication, sustained transdermal administration maintains extended systemic and local drug concentrations, effectively inhibiting inflammatory mediators such as NF- $\kappa$ B, COX-2, and pro-inflammatory cytokines [109,110].

**Pain and Musculoskeletal Conditions:** Transdermal patches containing curcumin can reduce localized inflammation, joint stiffness, and musculoskeletal discomfort. By modifying oxidative stress and inflammatory signaling pathways at the site of action, continuous drug release via the skin produces long-lasting analgesic effects and offers a non-invasive substitute for traditional analgesics [111].

**Dermatological Applications:** Transdermal and topical curcumin formulations have been investigated for the treatment of psoriasis, acne, eczema, and chronic wounds because of its antibacterial, wound-healing, and antioxidant qualities. While lowering systemic exposure and related toxicity, localized administration improves therapeutic effectiveness [112,113].

**Cancer Therapy and Chemoprevention:** In oncology, transdermal administration of curcumin has drawn interest due to its potential as an adjuvant cancer treatment and chemoprevention. Without the dose-limiting toxicity seen with large oral dosages, prolonged systemic exposure enables manipulation of several cancer-related pathways, such as apoptotic induction, blockage of angiogenesis, and reduction of tumor cell proliferation [114,115].

**Neurological and Neuro-inflammatory Disorders:** Transdermal systems have promise for the long-term treatment of neurodegenerative diseases including Alzheimer's and Parkinson's disease since curcumin demonstrates neuroprotective properties through antioxidant and anti-inflammatory pathways. Consistent brain exposure and therapeutic results are supported by enhanced pharmacokinetic stability via TDDS [116].

**Metabolic and Cardiovascular Disorders:** By lowering oxidative stress, inflammation, and lipid peroxidation, transdermal curcumin may help control metabolic syndrome, diabetes, and cardiovascular disorders. Continuous metabolic pathway regulation is ensured by sustained administration, which enhances glycemic management and protects the heart [117].

**Improved Patient Compliance and Safety:** Increased patient compliance as a result of less frequent dose, non-invasive administration, and prevention of gastrointestinal discomfort is a significant therapeutic advantage of transdermal curcumin systems. Because controlled drug release reduces systemic toxicity, TDDS is appropriate for long-term, chronic treatment [118].

#### **14. Recent Trends and Innovations in Curcumin Transdermal Technology**

**Nanocarrier-Integrated Transdermal Patches:** Incorporating nanocarriers into transdermal patches, including solid lipid nanoparticles (SLNs), polymeric nanoparticles, nanostructured lipid carriers (NLCs), and nanocrystals, is the subject of recent study. Through increased interaction with stratum corneum lipids, these systems promote skin penetration, increase curcumin solubility, and shield it from degradation [119,120].

**Systems of Vesicular Delivery:** For transdermal distribution of curcumin, advanced vesicular systems such as ethosomes, transfersomes, niosomes, and phytosomes have been extensively studied. Deeper penetration and better drug deposition within skin layers are made possible by their flexible lipid bilayers and high ethanol content, which disturb skin lipid packing [121,122].

**Transdermal Delivery Assisted by Microneedles:** Because microneedle-based technologies physically circumvent the stratum corneum barrier, they constitute a significant advance. Dissolving or hydrogel-forming microneedles loaded with curcumin allow for painless, regulated, and improved drug administration; they are especially well-suited for oncological and chronic inflammatory applications [123].


**Nanoemulgel and Hybrid Systems:** The benefits of nanoemulsions and gels are combined in hybrid formulations, such as nanoemulgel-loaded patches, which provide better drug loading, increased skin hydration, and controlled release. For the localized and systemic distribution of curcumin, these methods are being studied more and more [124].

**Stimuli-Responsive Transdermal Systems:** A new trend in transdermal technology is the ability of smart systems to react to physiological or environmental stimuli, such as temperature, pH, enzymes, or inflammation. By enabling site-specific and on-demand curcumin release, these devices enhance the accuracy and effectiveness of treatment [125].

**Bioadhesive and Biopolymer-Based Patches:** In order to improve patch adherence, skin compatibility, and residence time, the usage of bioadhesive polymers such as chitosan, hyaluronic acid, and alginate has grown. Additionally, biopolymer-based patches promote skin regeneration and reduce discomfort [126].

**3D Printing and Customized Transdermal Patches:** In order to promote personalized medicine strategies, additive manufacturing technologies are being investigated to create customized curcumin patches with exact control over dosage, size, and release kinetics [127].

**Combination and Synergistic Delivery Strategies:** In order to get synergistic therapeutic benefits and better clinical outcomes, recent research looks at combining curcumin with antioxidants, penetration enhancers, or other phytochemicals inside transdermal systems [128].



**Figure 10: Skin Irritation and Sensitization**

## 15. Challenges, Limitations, And Barriers in Curcumin Patch Development

**Poor Skin Permeability:** Because of the stratum corneum's highly organized lipid structure, curcumin has a limited permeability across intact skin, even with its favorable lipophilicity. Drug flow is severely limited by this barrier, requiring the adoption of penetration enhancers or sophisticated delivery devices, which might make formulation design more difficult [129].

**Limited Drug Loading and Low Aqueous Solubility:** Due to curcumin's very low water solubility, it might be difficult to achieve sufficient drug loading and even distribution in transdermal patch matrices. Drug crystallization, irregular release patterns, and decreased bioavailability can all be consequences of poor solubility [130].

**Problems with Chemistry and Photostability:** Curcumin is prone to deterioration in the presence of heat, light, and alkali. During formulation, storage, and administration, this instability may result in decreased drug efficacy, necessitating protective measures such as encapsulation or the use of stabilizing excipients [131].

**Skin Irritation and Safety Issues:** Using solvents, surfactants, or chemical penetration enhancers to increase curcumin penetration may result in skin irritation, erythema, or sensitization after extended usage. In patch development, ensuring skin safety while preserving enough permeability continues to be a crucial concern [132].

**Differences in Skin Permeation:** Dose adjustment can be complicated by variations in skin properties both between and within individuals, such as thickness, moisture level, age, anatomical location, and pathological conditions. These differences can lead to unpredictable absorption and inconsistent treatment effects [133].

**Insufficient Translational and Clinical Evidence:** There is limited clinical research verifying the effectiveness, safety, and long-term use of this approach, despite several in vitro and preclinical studies showing improved transdermal transport of curcumin. This gap hampers the commercialization and regulatory approval of curcumin patches [134].

**Table 3: Methods for Preparing Curcumin Transdermal Patches:**

Sr. No.	TECHNIQUE (COMMON NAME)	DESCRIPTION	PROCEDURE

1.	<b>SOLVENT CASTING /FILM CASTING</b>	A common lab-scale technique for creating homogeneous film patches involves dissolving a polymer or polymers, casting a drug-containing solution, and then evaporating the solvent.	1. Weigh the polymer or polymers and disintegrate curcumin (or curcumin dispersion) → 2. Dissolve the polymers in a suitably volatile solvent (such as ethanol, methanol, dichloromethane, or their mixtures) with plasticizer (such as PEG, glycerin) → 3. Disperse curcumin (which may require a co-solvent or surfactant like Tween 80) → 4. Pour the solution onto a level glass, plate, or backing membrane → 5. Let the solvent evaporate at room temperature or in a controlled oven → 6. Cut the patches, laminate them, and store them in a desiccator.
2.	<b>Matrix-type casting (single-layer matrix patch)</b>	In a polymeric matrix film, the drug is evenly distributed (drug diffuses through the matrix). HME or solvent casting is frequently used.	1. Choose a solvent, melt, and matrix polymer or polymers. 2. Evenly distribute curcumin in a polymer solution or melt (it may form a solid dispersion or nanosuspension beforehand) → 3. Cast or shape into a movie → 4. Dry and solidify 5. Use backing or glue to cut and back.

3.	<b>Reservoir (membrane-controlled) patch</b>	The medication formulation (gel or liquid) is kept in a reservoir behind a barrier that controls the rate at which it penetrates the skin.	1. Make a drug reservoir (a gel or liquid formulation containing dispersed or solubilized curcumin) → 2. Put the reservoir compartment together and cover it with a membrane that controls the rate. 3. Adhesive layers and laminate backing → 4. Cut and seal the repairs.
4.	<b>Electrospinning (curcumin-loaded nanofiber mats / fibrous patches)</b>	Creates curcumin-encapsulated polymer fiber nanofiber mats that can be used for wound-healing patches and long-term release.	1. Make a polymer solution (such as PCL, PEO, PVA, or PLGA) containing curcumin dissolved or dispersed (co-solvent or emulsion may be used for hydrophobic drugs). 2. Fill the syringe. 3. Electrospin onto the collector to maximize voltage, flow rate, and tip-to-collector distance → 4. Dry and crosslink (if necessary) 5. Cut the mats and laminate them to the backing if desired.
5.	<b>Hot-melt extrusion (HME) / Melt extrusion films</b>	Drug and polymer are continuously melted or extruded into films in this solvent-free technique, which is useful for creating amorphous dispersions and solvent-free production.	1. Combine curcumin (often as a powder or predried solid dispersion) with plasticizer and one or more thermoplastic polymers. 2. Put the mixture into the extruder and heat it to a temperature that can be melted or processed (below decomposition) → 3. To create film, extrude through a flat die. 4. Let cool, then cut into patches

			and laminate.
6.	<b>Microneedle patches (coat, dissolving or hollow MNs loaded with curcumin formulations)</b>	For medications with low permeability, such as curcumin, use micro-needles (solid coated, dissolving polymer needles, or hollow) to avoid the stratum corneum.	1. Select MN type (dissolving or coated) → 2a (coated): make a concentrated curcumin coating solution, spray or dip the MN array, and let it dry. 2b (dissolving MN): make a curcumin-containing polymeric formulation, cast it into MN molds, centrifuge it to fill the voids, and then dry it. 3. Store under desiccation after demolding.
7.	<b>Bilayer / Double-layer patches (e.g., backing + drug-loaded matrix or electrospun + cast layer)</b>	Adhesion, rate control, and reservoir functions can be combined using two or more layers. Electrospinning and casting are frequently combined.	1. Get the first layer ready (such as an electrospun mat or backing/adhesive). 2. Use electrospinning, casting, or spraying to apply a second drug-loaded layer. 3. Laminate, cut, and dry/solidify.
8.	<b>Spray coating / Solvent evaporation coating</b>	When the drug-polymer solution is sprayed over the backing or premade adhesive, the solvent evaporates, and a thin film coating is left behind.	1. Make a sprayable curcumin, polymer, and plasticizer suspension. 2. Use a pneumatic or air-spray nozzle to evenly spray over the backdrop. 3. Dry in a controlled environment → 4. Laminate and cut as necessary.

9.	<b>Nanocarrier-incorporated patches (niosomes / ethosomes / SLNs / liposomes embedded in a film)</b>	Create curcumin-loaded nanocarriers (such as ethosomes and niosomes) and add them to polymeric films to combine patch convenience with carrier benefits.	1. Use normal procedures to manufacture curcumin nanocarriers (ethosomes, niosomes, and SLN). 2. Cast onto the backing or combine carrier dispersion with polymer solution. 3. Gently dry (to maintain carrier integrity) → 4. Cut and assess patches.
10.	<b>Sol-gel / Composite ceramic-polymer matrices (for specialized wound patches)</b>	Adds curcumin to titania nanofibers or inorganic/organic hybrid matrices made from sol-gel (especially for wound patches).	1. Make sol (alkoxide hydrolysis) using curcumin or nanoparticles loaded with curcumin → 2. To create a mat, cast, spin, or electrospin 3. Gelation, drying, crosslinking, or moderate calcination (conditions modified to preserve curcumin).

**TABLE NO.4: ALTERNATIVE POLYHERBAL OPTIONS FOR CURCUMIN**

Sr. No.	Poly-Herbal Combination/ Plant	Key Active Phytochemicals	Therapeutic Relevance (Similar to Curcumin)	Why Considered an Alternative for Curcumin
1.	<b>BOSWELLIA SERRATA +</b>	Boswellic Acids,	Anti-inflammatory,	Strong COX/LOX inhibition similar to

How to cite this article: Kaur et al. (2026). **Unifying Herbal Medicine and Modern Pharmaceutical Delivery Via Curcumin Transdermal Patches**. Pan-African Journal of Health and Psychological Sciences. Vol.2, Issue 2, April-June 2026. <https://doi.org/10.64261/40brt540>.

	<b>GINGER EXTRACT</b>	Gingerols	analgesic	curcumin
<b>2.</b>	<b>ASHWAGANDHA + SHATAVARI</b>	Withanolides, Saponins	Adaptogenic, antioxidant, anti-stress	Systemic antioxidant effect comparable to curcumin
<b>3.</b>	<b>NEEM + TULSI FORMULATION</b>	Azadirachtin, Eugenol	Antimicrobial, wound healing	Effective for topical patches as antimicrobial alternative
<b>4.</b>	<b>GUDUCHI + AMLA COMBINATION</b>	Tinosporaside, Vitamin C	Immunomodulatory, antioxidant	High ORAC values similar to curcumin
<b>5.</b>	<b>TRIPHALA (AMLA + HARITAKI + BIBHITAKI)</b>	Polyphenols, Tannins	Anti-inflammatory, wound healing	Widely used for dermal and systemic antioxidant therapy
<b>6.</b>	<b>BRAHMI + MANDUKAPARNI</b>	Bacosides, Asiaticoside	Skin regeneration, anti-oxidant	Promotes collagen synthesis like curcumin
<b>7.</b>	<b>ALOE VERA + NEEM</b>	Aloin, Azadirachtin	Anti-inflammatory, soothing, antimicrobial	Strong topical action for transdermal patch base
<b>8.</b>	<b>LICORICE + TURMERIC-FREE POLYHERBAL GEL</b>	Glycyrrhizin, Flavonoids	Anti-redness, anti-irritant	Similar anti-inflammatory but better skin-friendly effect
<b>9.</b>	<b>GUGGUL + GINGER + PIPPALI</b>	Guggulsterone, Piperine	Anti-arthritic, bioenhancing	Piperine improves absorption similar to curcumin complexes
<b>10.</b>	<b>GOTU KOLA + CALENDULA</b>	Asiatic Acid, Triterpenes	Wound healing, skin repair	Effective in skin patches for repair and hydration
<b>11.</b>	<b>GREEN TEA EXTRACT + CHAMOMILE</b>	Catechins, Apigenin	Anti-oxidant, UV-protective	Stronger free-radical scavenging than curcumin in some models
<b>12.</b>	<b>GARLIC + GINGER POLYHERBAL</b>	Allicin, Gingerols	Anti-inflammatory,	Similar anti-inflammatory pathways (NF-κB

How to cite this article: Kaur et al. (2026). **Unifying Herbal Medicine and Modern Pharmaceutical Delivery Via Curcumin Transdermal Patches**. *Pan-African Journal of Health and Psychological Sciences*. Vol.2, Issue 2, April-June 2026. <https://doi.org/10.64261/40brt540>.

			antimicrobial	inhibition)
13.	<b>CLOVE + CINNAMON POLYHERBAL</b>	Eugenol, Cinnamaldehyde	Antioxidant, antimicrobial	High phenolic content comparable to curcumin
14.	<b>MORINDA CITRIFOLIA + ALOE VERA</b>	Iridoids, Aloin	Anti-inflammatory, antioxidant	Used for transdermal and wound gel formulations
15.	<b>SAFFRON + LICORICE</b>	Crocin, Glycyrrhizin	Anti-inflammatory, depigmenting	Topical applications similar to curcumin for skin patches

## 16. Future Prospects and Research Directions

It is anticipated that future studies on curcumin transdermal drug administration will concentrate on creating sophisticated, patient-centered, and clinically translatable delivery systems that can get beyond current formulation and biological obstacles. Achieving site-specific and on-demand drug release through the use of intelligent and stimuli-responsive transdermal systems that react to physiological cues like pH, temperature, enzymatic activity, or inflammatory markers has the potential to increase therapeutic precision and decrease systemic exposure [135]. Curcumin solubility, stability, and skin penetration are expected to be further improved by the integration of multifunctional nanocarriers, such as lipid-polymer hybrid nanoparticles, nanovesicular systems, and nanofiber-based patches, which will improve pharmacokinetic and pharmacodynamic results [136,137]. Precision medicine techniques may be supported by the creation of transdermal patches with individualized medication dosages, patch sizes, and release patterns made possible by developments in additive manufacturing and 3D printing technology [138]. Furthermore, to determine the long-term safety, effectiveness, and skin acceptability of curcumin transdermal systems—a crucial research gap—expanded clinical assessment through well planned human studies is necessary [139]. In order to improve patient acceptance and reduce skin irritation, future formulations are also anticipated to prioritize the use of natural polymers that are biodegradable and biocompatible [140]. Moreover, curcumin may have synergistic benefits when used in conjunction with other bioactive substances or traditional treatments to treat complicated chronic illnesses. The advancement of curcumin transdermal patches from experimental systems to clinically viable

therapeutic platforms will be largely dependent on ongoing translational research, regulatory standardization, and the investigation of new clinical indications [141-143].

## 17. Conclusion

Curcumin transdermal patches are an important scientific development that effectively combines the accuracy and effectiveness of contemporary medication delivery technology with the knowledge of traditional herbal therapy. Due to its limited water solubility, quick metabolism, and low oral bioavailability, curcumin—a well-known Ayurvedic substance with strong anti-inflammatory, antioxidant, antimicrobial, and wound-healing qualities—has long faced therapeutic restrictions.

By facilitating the prolonged, regulated, and targeted distribution of curcumin over the skin barrier, the creation of transdermal patches provides a clever and creative solution to these problems, improving pharmacological efficacy and systemic availability.

Curcumin patches made with polymers including HPMC, EC, PVP, and natural biopolymers show how herbal remedies can be combined with flexible pharmaceutical excipients. The design of patches with desired physicochemical and mechanical properties, such as flexibility, tensile strength, uniform drug distribution, controlled release kinetics, and minimal skin irritation, has been made possible by a variety of fabrication techniques, including solvent casting, film formation, nano-enhanced embedding, and reservoir-matrix hybrid systems.

Furthermore, the use of plasticizers, nanocarriers, and permeation enhancers has improved drug penetration through the stratum corneum, demonstrating that transdermal distribution can greatly get around the bioavailability restrictions connected to oral curcumin formulations.

From a medicinal perspective, curcumin transdermal patches have demonstrated encouraging outcomes in wound healing, arthritis, muscular discomfort, chronic inflammatory illnesses, and antioxidant treatment. Improved patient compliance, avoidance of first-pass metabolism, less frequent dose, and less gastrointestinal side effects are some of their main benefits. These advantages fit very nicely with worldwide trends toward patient-friendly, non-invasive drug delivery methods and a growing inclination for natural and herbal remedies.

Achieving industrial-scale standardization, guaranteeing batch-to-batch uniformity in herbal extracts, and maximizing curcumin's long-term stability inside polymer matrix are still difficult tasks. It is anticipated that developments in lipid-based carriers, intelligent

sensor-integrated patches, microneedle-assisted administration, and nanotechnology would further improve therapeutic efficacy and open up new clinical uses. Future research should emphasize robust in vivo studies, clinical trials, and regulatory guidance frameworks to support commercial translation of curcumin patches from laboratory innovation to widely accessible therapeutic products.

All things considered, curcumin transdermal patches are the perfect example of how traditional herbal expertise and contemporary pharmaceutical engineering may work together to provide phytoconstituents in a safe, efficient, and cutting-edge manner.

Such hybrid delivery methods will be essential in redefining herbal medicine, enhancing treatment results, and advancing next-generation transdermal drug delivery technologies as interest in natural medicines grows worldwide.

**\*Conflicts of Interest:** “The authors declare no conflicts of interest.”

## References

1. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*. 2014;4:177.
2. WHO. *Traditional Medicine Strategy 2014–2023*. World Health Organization; 2013.
3. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery. *Drug Discov Today*. 2009;14(15–16):804–811.
4. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. *Int J Biochem Cell Biol*. 2009;41(1):40–59.
5. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods*. 2017;6(10):92.

6. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin. *AAPS J.* 2013;15(1):195–218.
7. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin. *Mol Pharm.* 2007;4(6):807–818.
8. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
9. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.
10. Barry BW. Breaching the skin's barrier to drugs. *Nat Biotechnol.* 2004;22(2):165–167.
11. Ita K. Transdermal delivery of drugs with microneedles. *J Pharm Pharmacol.* 2015;67(7):821–827.
12. Naik A, Kalia YN, Guy RH. Transdermal drug delivery. *Adv Drug Deliv Rev.* 2000;56(5):619–628.
13. Williams AC, Barry BW. Penetration enhancers. *Adv Drug Deliv Rev.* 2012;64:128–137.
14. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as a therapeutic agent. *Biochem Pharmacol.* 2008;75(4):787–809.
15. Singh SP, et al. Transdermal drug delivery systems: a review. *Int J Pharm Sci Res.* 2011;2(7):1683–1693.
16. EMA. *Guideline on quality of herbal medicinal products.* European Medicines Agency; 2011.
17. Aggarwal BB, et al. Curcumin: the Indian solid gold. *Adv Exp Med Biol.* 2007;595:1–75.
18. Vogel H, Pelletier J. Curcumin isolation studies. *J Pharm.* 1815;1:289–300.
19. Gupta SC, et al. Therapeutic roles of curcumin. *AAPS J.* 2013;15(1):195–218.
20. Anand P, et al. Bioavailability of curcumin. *Mol Pharm.* 2007;4(6):807–818.
21. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.

22. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
23. Barry BW. Novel mechanisms and devices to enable transdermal drug delivery. *Eur J Pharm Sci.* 2001;14(2):101–114.
24. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.
25. Barry BW. Breaching the skin's barrier to drugs. *Nat Biotechnol.* 2004;22(2):165–167.
26. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
27. Guy RH, Hadgraft J. Transdermal drug delivery. *Drug Deliv.* 2003;10(2):75–82.
28. Williams AC, Barry BW. Penetration enhancers. *Adv Drug Deliv Rev.* 2012;64:128–137.
29. Ita K. Transdermal delivery of drugs with microneedles. *J Pharm Pharmacol.* 2015;67(7):821–827.
30. Touitou E, et al. Ethosomes—novel vesicular carriers. *J Control Release.* 2000;65(3):403–418.
31. Subash R, Revathi S, Akilandeswari S. Recent Advances in Transdermal Drug Delivery System and its Utilization in Herbal Medicines — a review of types, advancements, and effectiveness of herbal TDDS. *Pharmacognosy Research,* 2025;17(2):380–384.
32. Vichare SS et al. Transdermal Delivery of Herbal Extracts: Techniques, Polymers, and Permeation Enhancers — analysis of formulation methods and recent developments. *International Journal of Innovative Science and Research Technology,* 2025.
33. Hardainiyan S et al. A Review on Recent Innovations in Transdermal Drug Delivery for Herbal Therapy — overview of herbal TDDS and patch formulation. *Journal of Biomedical and Pharmaceutical Research,* 2014.
34. Patil V & Gosavi SB. Comprehensive Review of Transdermal Drug Delivery Systems: Mechanisms, Materials, and Modern Innovations — discussion of

- emerging nanocarrier technologies relevant to herbal actives. *Asian Journal of Pharmaceutical Research and Development*, 2025.
35. Barry BW. Breaching the skin's barrier to drugs. *Nat Biotechnol.* 2004;22(2):165–167.
  36. Elias PM. Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. *Exp Dermatol.* 1996;5(4):191–201.
  37. Brown MB, et al. Dermal and transdermal drug delivery systems: current and future prospects. *Drug Deliv.* 2006;13(3):175–187.
  38. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
  39. Mitragotri S, et al. Overcoming the skin barrier for transdermal drug delivery. *Nat Rev Drug Discov.* 2014;13(9):655–672.
  40. Elias PM. Epidermal lipids, barrier function, and desquamation. *J Invest Dermatol.* 1983;80(S1):44s–49s.
  41. Bouwstra JA, Ponc M. The skin barrier in healthy and diseased state. *Biochim Biophys Acta.* 2006;1758(12):2080–2095.
  42. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.
  43. Williams AC, Barry BW. Penetration enhancers. *Adv Drug Deliv Rev.* 2012;64:128–137.
  44. Lademann J, et al. Hair follicles—an efficient storage and penetration pathway. *Skin Pharmacol Physiol.* 2005;18(3):123–128.
  45. Elias PM. Stratum corneum architecture, metabolic activity and interactivity. *Exp Dermatol.* 1996;5(4):191–201.
  46. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of penetration enhancers. *Adv Drug Deliv Rev.* 2002;54(S1):S41–S55.
  47. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
  48. Barry BW. Breaching the skin's barrier to drugs. *Nat Biotechnol.* 2004;22(2):165–167.

49. Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. *Int J Pharm.* 2005;305(1–2):2–12.
50. Anand P, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007;4(6):807–818.
51. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods.* 2017;6(10):92.
52. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
53. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.
54. Karri VVSR, et al. Transdermal delivery of curcumin. *Eur J Pharm Sci.* 2015;78:68–77.
55. Anand P, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007;4(6):807–818.
56. Ireson CR, et al. Metabolism of curcumin in human and rat intestine. *Cancer Epidemiol Biomarkers Prev.* 2001;10(2):103–111.
57. Wang YJ, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. *J Pharm Biomed Anal.* 1997;15(12):1867–1876.
58. Lao CD, et al. Dose escalation of curcuminoids in humans. *BMC Complement Altern Med.* 2006;6:10.
59. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods.* 2017;6(10):92.
60. Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. *Int J Pharm.* 2005;305(1–2):2–12.
61. Karri VVSR, et al. Transdermal delivery of curcumin. *Eur J Pharm Sci.* 2015;78:68–77.
62. Puglia C, et al. Curcumin-loaded lipid nanoparticles. *Drug Deliv.* 2014;21(4):231–240.
63. Shakeel F, et al. Nanoemulsions as transdermal drug delivery systems. *Curr Drug Deliv.* 2012;9(4):337–351.

64. Semalty A, et al. Phytosome technology for herbal drug delivery. *Fitoterapia*. 2010;81(5):306–314.
65. Prausnitz MR. Microneedles for transdermal drug delivery. *Adv Drug Deliv Rev*. 2004;56(5):581–587.
66. Touitou E, et al. Ethosomes—novel vesicular carriers. *J Control Release*. 2000;65(3):403–418.
67. Cevc G, Blume G. New, highly efficient formulation of diclofenac. *Biochim Biophys Acta*. 2001;1514(2):191–205.
68. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes). *Int J Pharm*. 1998;172(1–2):33–70.
69. Gupta H, et al. Nanogels as a carrier for topical drug delivery. *Drug Discov Today*. 2016;21(2):360–372.
70. Kalia YN, et al. Iontophoretic drug delivery. *Adv Drug Deliv Rev*. 2004;56(5):619–658.
71. Mitragotri S. Healing sound: ultrasound-assisted drug delivery. *Nat Rev Drug Discov*. 2005;4(3):255–260.
72. Anand P, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807–818.
73. Yallapu MM, et al. Curcumin: a review of its therapeutic applications. *Drug Discov Today*. 2012;17(1–2):71–80.
74. Karri VVSR, et al. Transdermal delivery of curcumin. *Eur J Pharm Sci*. 2015;78:68–77.
75. Wang YJ, et al. Stability of curcumin in buffer solutions. *J Pharm Biomed Anal*. 1997;15(12):1867–1876.
76. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids. *Z Lebensm Unters Forsch*. 1985;180:132–134.
77. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol*. 2008;26(11):1261–1268.
78. Anand P, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807–818.

79. Yallapu MM, et al. Curcumin: therapeutic applications and delivery systems. *Drug Discov Today*. 2012;17(1–2):71–80.
80. Guy RH, Hadgraft J. *Transdermal Drug Delivery*. 2nd ed. New York: Marcel Dekker; 2003.
81. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv*. 2006;13(3):175–187.
82. Rao PR, Diwan PV. Formulation and evaluation of polymeric films. *Drug Dev Ind Pharm*. 1997;23(3):327–333.
83. Williams AC, Barry BW. Penetration enhancers. *Adv Drug Deliv Rev*. 2012;64:128–137.
84. Karri VVSR, et al. Transdermal delivery of curcumin. *Eur J Pharm Sci*. 2015;78:68–77.
85. Benedek I, et al. Pressure-sensitive adhesives for transdermal systems. *Drug Dev Ind Pharm*. 1999;25(3):323–331.
86. Hadgraft J. Skin, the final frontier. *Int J Pharm*. 2001;224(1–2):1–18.
87. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol*. 2008;26(11):1261–1268.
88. Yallapu MM, et al. Curcumin delivery using polymeric nanoparticles. *Drug Discov Today*. 2012;17(1–2):71–80.
89. Puglia C, et al. Curcumin-loaded lipid nanoparticles. *Drug Deliv*. 2014;21(4):231–240.
90. Elsayed MMA, et al. Deformable liposomes and transdermal delivery. *Int J Pharm*. 2007;332(1–2):1–16.
91. Touitou E, et al. Ethosomes—novel vesicular carriers. *J Control Release*. 2000;65(3):403–418.
92. Cevc G, Blume G. Transfersomes for transdermal drug delivery. *Biochim Biophys Acta*. 2001;1514(2):191–205.
93. Gupta H, et al. Nanogels as carriers for topical drug delivery. *Drug Discov Today*. 2016;21(2):360–372.

94. Prausnitz MR. Microneedles for transdermal drug delivery. *Adv Drug Deliv Rev.* 2004;56(5):581–587.
95. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
96. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.
97. Guy RH. Current status and future prospects of transdermal drug delivery. *Pharm Res.* 1996;13(12):1765–1769.
98. Williams AC, Barry BW. Penetration enhancers. *Adv Drug Deliv Rev.* 2012;64:128–137.
99. Hadgraft J, Lane ME. Skin permeation: fundamentals and application. *Adv Drug Deliv Rev.* 2016;97:3–13.
100. Anand P, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007;4(6):807–818.
101. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med.* 1998;64(4):353–356.
102. Guy RH. Transdermal drug delivery. *Pharm Res.* 1996;13(12):1765–1769.
103. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261–1268.
104. Hadgraft J, Lane ME. Skin permeation: fundamentals and application. *Adv Drug Deliv Rev.* 2016;97:3–13.
105. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. *Int J Biochem Cell Biol.* 2009;41(1):40–59.
106. Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. *Nat Prod Rep.* 2011;28(12):1937–1955.
107. Yallapu MM, et al. Therapeutic applications of curcumin nanoformulations. *AAPS J.* 2015;17(6):1341–1356.
108. Brown MB, et al. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187.

109. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. *Int J Biochem Cell Biol.* 2009;41(1):40–59.
110. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods.* 2017;6(10):92.
111. Henrotin Y, et al. Curcumin for the management of osteoarthritis. *Alternative Ther Health Med.* 2014;20(Suppl 2):S3–S10.
112. Vaughn AR, et al. Natural oils for skin barrier repair. *Int J Mol Sci.* 2018;19(1):70.
113. Sidhu GS, et al. Curcumin enhances wound healing. *Wound Repair Regen.* 1998;6(2):167–177.
114. Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. *Nat Prod Rep.* 2011;28(12):1937–1955.
115. Tomeh MA, et al. Curcumin and cancer. *Nutrients.* 2019;11(4):880.
116. Mythri RB, Bharath MMS. Curcumin: a potential neuroprotective agent. *Int J Pharm Sci Rev Res.* 2012;14(2):30–36.
117. Panahi Y, et al. Curcumin and metabolic syndrome. *Phytother Res.* 2017;31(12):1827–1846.
118. Hadgraft J, Lane ME. Advanced transdermal drug delivery systems. *Eur J Pharm Sci.* 2016;92:2–17.
119. Karri VVSR, et al. Transdermal delivery of curcumin. *Eur J Pharm Sci.* 2015;78:68–77.
120. Puglia C, et al. Lipid nanoparticles for dermal delivery of curcumin. *Drug Deliv.* 2014;21(4):231–240.
121. Touitou E, et al. Ethosomes—novel vesicular carriers. *J Control Release.* 2000;65(3):403–418.
122. Elsayed MM, et al. Transfersomes as a transdermal delivery system. *Int J Pharm.* 2007;332(1–2):1–16.
123. Prausnitz MR. Microneedles for transdermal drug delivery. *Adv Drug Deliv Rev.* 2004;56(5):581–587.

124. Gupta H, et al. Nanoemulgel-based drug delivery systems. *Drug Discov Today*. 2016;21(2):360–372.
125. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. *Adv Drug Deliv Rev*. 2012;64:49–60.
126. Dhawan S, et al. Biopolymer-based transdermal systems. *J Control Release*. 2019;299:119–134.
127. Genina N, et al. 3D printing of drug delivery systems. *Pharmaceutics*. 2020;12(3):298.
128. Yallapu MM, et al. Therapeutic applications of curcumin nanoformulations. *AAPS J*. 2015;17(6):1341–1356.
129. Hadgraft J, Lane ME. Skin permeation: fundamentals and application. *Adv Drug Deliv Rev*. 2016;97:3–13.
130. Anand P, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807–818.
131. Wang YJ, et al. Stability of curcumin in buffer solutions. *J Pharm Biomed Anal*. 1997;15(12):1867–1876.
132. Williams AC, Barry BW. Penetration enhancers. *Adv Drug Deliv Rev*. 2012;64:128–137.
133. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol*. 2008;26(11):1261–1268.
134. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods*. 2017;6(10):92.
135. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. *Adv Drug Deliv Rev*. 2012;64:49–60.
136. Karri VVSR, et al. Transdermal delivery of curcumin. *Eur J Pharm Sci*. 2015;78:68–77.
137. Puglia C, et al. Hybrid nanocarriers for dermal delivery. *Drug Deliv*. 2014;21(4):231–240.
138. Genina N, et al. 3D printing of personalized drug delivery systems. *Pharmaceutics*. 2020;12(3):298.

139. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods*. 2017;6(10):92.
140. Dhawan S, et al. Biocompatible polymers in transdermal drug delivery. *J Control Release*. 2019;299:119–134.
141. Yallapu MM, et al. Synergistic therapeutic applications of curcumin nanoformulations. *AAPS J*. 2015;17(6):1341–1356.
142. Brown MB, et al. Regulatory challenges in transdermal drug delivery. *Drug Deliv*. 2006;13(3):175–187.
143. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. *Int J Biochem Cell Biol*. 2009;41(1):40–59.